Oui
Chitosan Vaginal Tablets
- User: Female
- Hormonal: Non-Hormonal
-
Delivery type:
- Vaginal - Other
-
Intended Duration:
- Pericoital
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): Cirqle Biomedical, Organon
Details
- API: Chitosan
- Target: Mucin
-
Mechanism of Action:
- Cervical Mucus Changes
- Regimen: On Demand
- MPT: Not Potential MPT
- Promising Attributes: Developers suggest that an on-demand non hormonal alternative to spermicides or barrier methods may reach a portion of the contraceptive market moving away from both traditional barrier methods and hormonal options.
Product Status
Active Pre-Clinical Research
History
2019: Cirqle Biomedical completes first seed funding round, announces intent to further develop a chitosan-based on-demand contraceptive that will thicken cervical mucus to prevent sperm movement into the uterus.
2020: Cirqle receives support from NIH and EU Eurostars (a program funded by the European Union) to advance pre-clinical development
2022: Cirqle announces milestone partnership with Organon to further develop and commercialize their product, Oui.
2023: Cirqle announces a 98% average decrease in sperm reaching the uterus in sheep who have had Oui's prophylactic gel placed on their cervix, compared to untreated sheep